Clinical trial · Observational
Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma
NCT04423549CI-TRIAL-00045439unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the predictive value of a mRNA signature and liquid biopsy in patients with Diffuse Large B cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- tested group
- label
- controlled group
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 5-years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * biopsy proved Diffuse Large B cell Lymphoma * newly diagnosed between 2000-01 and 2015-12 Exclusion Criteria: * patients with biopsy samples unavailable
References
Publications (0)
Data not yet available
No reference posted for this study.